The Annual General Meeting of Eckert & Ziegler SE (ISIN DE0005659700) today approved the proposal of the Executive Board and Supervisory Board and resolved to pay a dividend of EUR 0.22 per share (previous year: EUR 0.17) for the 2025 fiscal year. This represents a 29% increase from the prior year, signaling the company's robust financial health and confidence in its future prospects.
As in previous years, the Annual General Meeting was held as an in-person event, right next to the Eckert & Ziegler SE headquarters in Berlin. In total, 55.37% of the company's share capital was represented. The Annual General Meeting endorsed the members of the Executive Board and the Supervisory Board of Eckert & Ziegler SE for the 2025 fiscal year and approved all items on the agenda by a large majority.
The detailed voting results of the Annual General Meeting and the CEO's presentation are available on the Eckert & Ziegler SE website: https://www.ezag.com/investors/annual-general-meeting/.
Eckert & Ziegler SE, with more than 1,000 employees, is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
The dividend increase underscores the company's strong financial performance and its commitment to delivering value to shareholders. This decision comes amid a favorable environment for nuclear medicine, driven by advancements in diagnostic imaging and targeted radionuclide therapies. As the demand for radiopharmaceuticals grows, Eckert & Ziegler is well-positioned to capitalize on these trends, supported by its comprehensive service offerings and expertise in isotope technology.
Investors and analysts will likely view the dividend hike positively, as it reflects management's confidence in the company's cash flow generation and future earnings potential. The strong shareholder turnout and approval of all agenda items further demonstrate alignment between the board and investors.
